Washington State Department of Health

ELABORATIONS

News and Issues for Washington's Clinical Laboratories

Volume IX Issue 3 April 2004

Proposed Changes to Medical Test Site Rules

by Gail Neuenschwander

Revisions to the federal CLIA regulations were published in the January 24, 2003 Federal Register. The changes were effective April 24, 2003. The state Medical Test Site (MTS) Rules, Chapter 246-338 WAC, will now be changed so they are consistent with the CLIA regulations. The MTS rules must be at least as stringent as CLIA in order for Washington laboratories to maintain an exemption from federal CLIA regulation.

Following is a summary of the proposed changes to the MTS rules. The changes will be made through the official state rulemaking process. Notification will be sent to all Medical Test Sites when the appropriate documents are filed and the hearing date is set.

If you need a copy of the current MTS rules, you can download from the web at: www.leg.wa.gov/wac. Select Title 246 - Health, Department of; select 246-338 Medical Test Site rules.

Send any comments that you have on the proposed changes by **April 30, 2004** to:

Gail Neuenschwander
Email: gail.neuenschwander@doh.wa.gov
Fax: (206)361-2813
Mail: DOH/LQA
1610 NE 150th St.
Shoreline, WA 98155

WAC 246-338-010 Definitions

- Calibration verification - changed wording in the definition from assaying of calibration materials to assaying of materials of known concentration;
- HCFA changed to CMS - Centers for Medicare & Medicaid Services;
- Subspecialty - updated subspecialty categories to eliminate other chemistry, other hematology and other immunohematology; changed blood group to ABO Grouping and crossmatching to compatibility testing;

WAC 246-338-060(1)(c) Personnel

- Eliminated the language regarding the grandfather clause for persons who passed an exam for director conducted by United States Public Health Service prior to July 1, 1970, as this is part of the CLIA personnel standards which are cross-referenced (42 CFR Part 493 Subpart M);

WAC 246-338-070 Records

Requisitions (1)

- Added language: (b) Name and address or other suitable identifiers of the authorized person ordering the test;

continued on page 2

Inside This Issue

Practice Guidelines

The following practice guidelines have been developed by the Clinical Laboratory Advisory Council. They can be accessed at the following website:
www.doh.wa.gov/lqa.htm

Anemia	Lipid Screening
ANA	Point-of-Care Testing
Bioterrorism Event Mgmt	PSA
Bleeding Disorders	Red Cell Transfusion
Chlamydia	Renal Disease
Diabetes	STD
Group A Strep Pharyngitis	Thyroid
Hepatitis	Tuberculosis
HIV	Urinalysis
Intestinal Parasites	Wellness

Proposed Changes to MTS Rules, continued from page 1

- Revised language: (f) Sex and age of patient or date of birth of the patient ~~if appropriate~~;

Test Reports (3)

- Added additional language that must be included on the test report: (c) Patient name and identification number, or a unique patient identifier and identification number; specimen source, when appropriate;

Cytology Reports (4)

- Updated reference to the 2001 Bethesda system of terminology;

Cytogenetic Reports (6)

Updated language:

- (b) Include the number of cells counted and ~~karyotyped~~ analyzed;
- (c) Include a summary and interpretation of the ~~karyotypes findings~~ observations; and
- (d) Use the International System for Cytogenetic Nomenclature;

Record/Slide/Tissue Retention Schedule

Added language:

- (8) The medical test site must retain records, slides and tissues as described in Table 070-1, under storage conditions that ensure proper preservation;
- (9) If the medical test site does not have sufficient space to store all records on-site, the records must be retrievable within a reasonable period of time, not to exceed 48 hours;

Table 070-1

- Clarified that test records include instrument printouts, if applicable;

WAC 246-338-080 QUALITY ASSURANCE

Added language:

- (2) The quality assurance plan must include mechanisms or systems to:
  - (h) Ensure that specimens are properly labeled, including patient name or unique patient identifier and, when appropriate, specimen source;
  - (i) Ensure confidentiality of patient information through all phases of the testing process;
- (4) When results of control or calibration materials fail to meet the established criteria for acceptability, the medical test site must have a system in place to determine if patient test results have been adversely affected. The system must include:
  - (a) A review of all patient test results obtained in the unacceptable test run; and
  - (b) A review of all patient test results since the last acceptable test run.
- (6) The owner must:
  - (b) Ensure that molecular amplification procedures that are not contained in closed systems have a uni-directional workflow. This must include separate areas for specimen preparation, amplification and production detection, and as applicable, reagent preparation;
  - (c) Establish, ~~post~~ make accessible, and observe safety precautions to ensure protection from physical, chemical, biochemical, and electrical hazards and biohazards;

WAC 246-338-090 QUALITY CONTROL

Added language:

- (6) (g) Rotate control material testing among all persons who perform the test;
- (7) Validation for moderate complexity testing: If using the reference range provided by the manufacturer, verify that it is appropriate for the patient population;

continued on page 3

ELABORATIONS is a free monthly publication of the Washington State Department of Health (DOH) Public Health Laboratories (PHL) and Office of Laboratory Quality Assurance (LQA).

Secretary, DOH: Mary Selecky
Health Officer: Maxine Hayes, MD, MPH
Director, PHL: Romesh Gautom, PhD
Program Manager, LQA: Gail Neuenschwander
Editor: Leonard Kargacin (206) 361-2804
Circulation: Leonard Kargacin (206) 361-2804

Comments, letters to the editor, information for publication, and requests for subscription can be directed to:
ELABORATIONS
Washington State Public Health Labs
1610 NE 150th Street
Shoreline, WA 98155

e-mail address: leonard.kargacin@doh.wa.gov

NOTE: Letters to the editor may be published unless specified otherwise by the author.

Website addresses:
DOH home page: http://www.doh.wa.gov
LQA home page: http://www.doh.wa.gov/lqa.htm
PHL home page:
http://www.doh.wa.gov/EHSPHL/PHL/default.htm

Proposed Changes to MTS Rules, continued from page 2

Table 090-1 General Quality Control Requirements

- Added immunohistochemical stains to types of stains that must have positive and negative controls run with each time of use;

- **Eliminated Table 090-2 Calibration and Calibration Checks - Moderate Complexity Testing**;

- **Renamed Table 090-3 Calibration and Calibration Checks - High Complexity Testing** to Table 090-2 Calibration and Calibration Verification - Moderate and High Complexity Testing, as the requirements for calibration and calibration verification now apply to both moderate and high complexity testing;

Table 090-5 Quality Control Procedures - Hematology

- Automated: Changed the requirement for 2 levels of reference materials every 8 hours to 2 levels each day of testing;

Table 090-7 Quality Control Procedures - General Immunology

- Changed the language: ~~Moderate complexity~~ Kits with procedural (internal) controls;

Syphilis Serology (090)(9)(e)

- Changed the requirement for testing positive and negative reference materials with each test run to each day of testing;

Tables 090-8 & 9 Quality Control Procedures - Bacteriology & AST

- Changed the QC requirements from each day or week of use to each batch, shipment and new lot number for catalase, coagulase, oxidase, beta-lactamase Cefinase reagents, bacitracin, optochin, ONPG, X and V disks or strips;
- Changed acid-fast stain QC from each week of use to each day of use;
- Changed antisera QC from each month of use to every six months;
- Updated NCCLS references;

Table 090-10 Quality Control Procedures - Mycobacteriology

- Revised language to read that QC for all reagents or test procedures used for mycobacteria identification must be done using an acid-fast organism that produces a positive and negative reaction each day of use, unless otherwise specified;
- Changed acid-fast stain QC requirements to a positive and negative each day of use;
- Changed fluorochrome acid-fast stain QC to each time of use;
- Clarified that each batch of media, and each shipment lot of antimycobacterial agents used for susceptibility testing must have QC performed before or concurrent with initial use;

Table 090-11 Quality Control Procedures - Mycology

- Added: QC for lactophenol cotton blue stain must be done each batch or shipment and each lot number;
- Changed the QC requirement for acid-fast stains from each week to each day of use;
- Changed QC for reagents for biochemical and other identification test procedures from each week of use to each batch or shipment and lot number;

Cytology (090)(9)(h)

- (ii)(D) Clarified that when counting slides for the 100 slides/day limit, that slide preparation techniques (automated, semi-automated or liquid based) which results in cell dispersion over one-half or less of the total available slide may be counted as one-half slide for nongynecologic slides, NOT for gynecologic slides;
- (iii)(D) Added language that records of initial examination and rescreening results are available and documented;
- (iii)(G) Changed the requirement for correlation with histopathology reports of all abnormal cytology reports to all HSIL, adenocarcinoma, or other malignant neoplasms;

Immunohematology/Transfusion Services (090)(9)(i)

- Updated FDA citations;

Histocompatibility (090)(9)(j)

- Updated CLIA cross-reference;

Cytogenetics (090)(9)(k)

Revised language:

- (i) Document:
  - (D) Reactions observed;
  - (F) Sufficient resolution appropriate for the type of tissue or specimen and the type of study required based on the clinical information provided ~~to support the reported results~~;
  - (iv) Perform ~~confirmatory testing on all atypical results when performing~~ full chromosome analysis for determination of sex ~~by X and Y Chromatin counts~~;

Correct Coding And Clinician Fees - Online Help

by Leonard Kargacin

The following information is based in part from an article in the September 12, 2003 *National Intelligence Report*, a newsletter published for the clinical laboratory industry by Washington G-2 Reports in Washington, D.C. Additional information has been provided by Tammy Ewers from Noridian Medicare Part B.

The Centers for Medicare & Medicaid Services (CMS) has posted on its website the automated edits (updated quarterly) that contractors use to target questionable claims and adjust payments to indicate what would have been paid if the claims had been filed correctly. Previously, you had to subscribe with the National Technical Information Service to get the edits. The next quarterly update is effective April 1, 2004 and will be available shortly after that.

The edits, known as the National Correct Coding Initiative, identify pairs of services, including laboratory services that typically should not be billed by the same provider for the same patient on the same day. The edits involve comprehensive/component code combinations and mutually exclusive codes. They are posted online at: http://www.cms.hhs.gov/physicians/cciedits/. Please note, the heading Comprehensive/Component Edits has been changed to the heading Column 1/Column 2 Correct Coding Edits. The table containing comprehensive/component edits also includes edits which do not involve a comprehensive/component relationship, but are codes that should not be reported together for other reasons, for example, **misuse of the code**, etc. The headings have been changed to more accurately reflect the overall category of the edits within the tables and to eliminate the confusion of using the term(s) ìcomprehensive/componentî.

The CMS website also has a physician fee lookup service online. This enables pathologists and other clinicians to see in advance what Medicare will pay for a particular service or range of services under its physician fee schedule. Rates shown include both the unadjusted fees as well as fees adjusted for geographic practice cost differences. The website is: http://www.cms.hhs.gov/physicians/mpfsapp/default.asp.

MTS Database Updates

by Leonard Kargacin

The Medical Test Site (MTS) Rules are contained in Washington Administrative Code (WAC) 246-338. Section 026 of this WAC defines the Notification Requirements for those facilities licensed as a MTS. The following are excerpts from this section of the WAC:

The owner must notify the department (Department of Health/LQA) in writing at least thirty days prior to the date of opening or closing the medical test site. In addition, the owner must notify the department in writing within thirty days of any changes in:

- name of site;
- director;
- location of site;
- tests, specialties and subspecialties; and
- test methodologies.

For a full copy of the WAC, please refer to the LQA website at: www.leg.wa.gov/wac.

Basic Courses in Urine Sediments

Dates: May 11, 2004 or May 12, 2004 **Registration Fee:** $105.00
Course Length: 1 day

These one-day classes emphasize recognizing elements in urine sediments. Participants will perform actual microscopic examination of urine sediments and review reference slides. Also included in the course will be pertinent lectures regarding quality assurance, quality control, correlation of results, collection of adequate specimens, and basic kidney physiology.

WHO SHOULD ATTEND: This training session is designed for persons examining urine sediments in hospital laboratories, physician office labs, clinics, and other testing sites.

CONTINUING EDUCATION UNITS: Students will receive 0.6 CEUs for completion of this course. Applicants must plan to attend the entire workshop to receive CEUs.

If you would like more information about this class, call Shelley Lankford, Training Program Manager, at (206) 361-2810 or email the training Program at PHL.training@doh.wa.gov. You can also download training registration forms at the Public Health Laboratories Training Program website at http://www.doh.wa.gov/EHSPHL/PHL/train.htm.

Basic Urine Sediments Training Course

Registration Form

Name:_____

Employer:_____

Employer Address:_____

City:_____ State: _____ Zip:_____

Work Phone:_____FAX:_____

E-mail:_____ Message Phone:_____

Class Date (check one): _____Tuesday, May 11, 2004 or
_____Wednesday, May 12, 2004

HOW TO REGISTER: Complete the registration form and mail to the **Department of Health, PHL Training Program, 1610 NE 150th Street, PO Box 550501, Shoreline, WA 98155-9701** or fax to: **(206) 361-2904**. A confirmation packet will be sent to you by mail. The packet will contain your registration confirmation, payment instructions, and a map to the course location. Please **do not** send money with your registration form.

Registration Fee: $105.00 **Registration Deadline:** Friday, April 30, 2004

Waived Testing Helpful Hints

A self-study PowerPoint presentation on Good Laboratory Practices can be found on the following website: http://www.doh.wa.gov/lqa.htm

***Select** the sidebar: Updates*
***Select** : Good Laboratory Practices with Waived Test Systems*

NOTE: You do not need to have the Microsoft PowerPoint software loaded on your system to view this document.

Calendar of Events

PHL Training Classes:
(http://www.doh.wa.gov/EHSPHL/PHL/train.htm)

Urine Sediments

May 11	Shoreline
May 12	Shoreline

WSSCLS/NWSSAMT Spring Meeting

April 29-May 1	Vancouver

Northwest Medical Laboratory Symposium

October 20-23	Portland

11th Annual Clinical Laboratory Conference

November 8	Seattle

Contact information for the events listed above can be found on page 2. The Calendar of Events is a list of upcoming conferences, deadlines, and other dates of interest to the clinical laboratory community. If you have events that you would like to have included, please mail them to ELABORATIONS at the address on page 2. Information must be received at least one month before the scheduled event. The editor reserves the right to make final decisions on inclusion.

ELABORATIONS
Washington State Department of Health
1610 NE 150th Street
Shoreline, WA 98155